Please assess the completion status of the following clinical trial:

Trial Title: HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all of the following inclusion criteria in order to be entered into the study:~1. Age 18 or older~2. Patient has signed informed consent~3. Patient must have a diagnosis of hepatocellular cancer confirmed by at least one of the following:~i. Histological confirmation ii. Magnetic resonance imaging (MRI) result with early enhancement and delayed enhancement washout of at least one solid liver lesion \> 1 cm. Patient must also have evidence of cirrhosis or have chronic hepatitis B.~iii. Contrast enhanced computed tomography (CT) with early enhancement and delayed enhancement washout of at least one solid liver lesion \> 1cm. Patient must also have evidence of cirrhosis or have chronic hepatitis B.~d. Patient must not be suitable for treatment by resection or percutaneous ablation at time of study entry.~Patients not suitable for ablation due to lesion location may be enrolled~e. Patient MUST meet at least ONE of the following criteria:~i. Stage Child-Pugh B 7 ii. Recurrent HCC iii.Performance status ECOG 1~f. Patient has a life expectancy of at least 6 months~g. Absence of occlusive thrombus to the main portal trunk~Exclusion Criteria:~If patients meet any of the following criteria they may not be entered into the study:~1. Current or previous treatment with chemo- or radiation therapy or sorafenib~2. Previous treatment with any form of transarterial embolization for HCC~3. Patients with current or history of any other cancer except non-melanomatous skin cancer~4. Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive~5. Performance status ECOG \> 2~6. Child-Pugh scores \>7~7. Active gastrointestinal bleeding~8. Evidence of uncorrectable bleeding diathesis~9. Extra-hepatic spread of the HCC~10. Total Bilirubin \> 3 mg/dL~11. \>50% tumor involvement of the liver~12. Infiltrative or diffuse HCC~13. Encephalopathy not adequately controlled medically~14. Presence of ascites not controlled medically~15. Presence of medically relevant localized or systemic infection, other than hepatitis B, C, D, E or G~16. Any contraindication for MRI (eg. metallic implants)~17. Allergy to contrast media that cannot be managed with prophylaxis~18. Allergy to iodized oil~19. Any contraindication to arteriography~20. Any contraindication for doxorubicin administration, including the following:~i. White Blood Cell count (WBC) \<3000 cells/mm₃~ii. Absolute Neutrophil \<1500 cells/mm₃~iii. Cardiac ejection fraction \<50%~iv. Other condition deemed exclusionary by physician~u. Any contraindication for hepatic embolization, including the following:~i. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior to chemoembolization~ii. Hepatofugal blood flow~iii. Serum creatinine \> 2mg/dL~iv. Uncorrectable impaired clotting~1. Platelet \<50,000/mm₃~2. International Normalized Ratio (INR) \> 1.4~3. Activated Prothrombin Time (aPTT) less than 21 or greater than 40~   v. AST \> 5X upper limit of normal for lab~   vi. ALT \> 5X upper limit of normal for lab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HepaSphere/QuadraSphere TACE (Type: EXPERIMENTAL): HepaSphere/QuadraSphere TACE
- Conventional TACE (Type: ACTIVE_COMPARATOR): Conventional TACE

Based on this trial design, predict the completion outcome and termination type (if applicable).